Ranbaxy:: may see some recovery after the company clarified that its deal with Daiichi is on track. Earlier reports stated production at three facilities of Ranbaxy Laboratories could be banned if charges of fraud, forging of documents and manufacturing from unapproved locations leveled by USFDA are proved.